Investor Relations

VBL Therapeutics (Nasdaq: VBLT) is seeking to improve care for cancer and immune-inflammatory diseases by inventing targeted medicines with the potential for broad impact. For additional information and catalysts, see our corporate presentation.

Press Releases

August 2, 2022
VBL Therapeutics Announces Workforce Reduction
Read More
July 19, 2022
VBL Therapeutics Announces Top-Line Data from Phase 3 OVAL Trial of Ofra-Vec in Patients with Platinum-Resistant Ovarian Cancer
Read More

Events & Presentations

More events are coming soon.

Corporate Presentation

Company Presentation July 2022
August 14, 2022 8:13 PM EDT

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Stock Chart